Top Ten articles in the pharma industry this week

pharmafile | October 21, 2016 | News story | Medical Communications biggest stories, news, week, weekly 

This week has seen a few big collaboration and partnerships occur, whilst there have been some major movements within immunotherapy cancer treatments. Read here to catch up on the biggest news stories that have been viewing on our website.

10. IBM and Quest forge precision cancer treatment partnership

The two companies come together to launch IBM Watson for Genomics, a service which combines the cognitive computing ability of the tech giant’s technology with Quest’s tumour analysis.

9. MSD’s antiviral drug hits endpoint targets in Phase III trials

MSD, known as Merck in the US, announced that their Phase III clinical study of letermovir, an investigational antiviral medicine, met its primary endpoints in trials.

8. Regeneron and Teva’s experimental drug halted by FDA clinical hold

Regeneron and Teva’s fasinumab was halted mid-trial when it was found that a patient suffered adjudicated arthropathy after being given a high dose of fasinumab.

7. Celgene trial displays promising results for Crohn’s disease alternative treatment

Celgene Corporation has published positive news from a Phase Ib trial for the treatment of Crohn’s disease.

6. Pfizer sets release date for rival to J&J’s blockbuster drug

Pfizer announced that they will release its biosimilar to Johnson & Johnson’s Remicade in late November of this year.

5. Hanmi Pharmaceutical raided over insider trading suspicions

Hanmi Pharmaceutical’s headquarters in Seoul were raided by South Korean prosecutors as part of a probe into suspicious trading that occurred before the news release of a major trade deal collapse.

4. Apitope reclaims multiple sclerosis treatment from Merck after 7 years

Firm regains multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the first time since it granted the rights to the German firm in 2009 to develop and commercialise the compound.

3. Roche’s immunotherapy cancer drug given FDA approval

Roche’s anti-PD-L1 cancer immunotherapy drug is approved by the FDA for the treatment of metastatic non-small cell lung cancer.

2. Novartis in collaboration deal worth potential $1.2 billion with Cerulean

Novartis has agreed a collaboration deal with Cerulean Pharma to develop and market potential nanoparticle-drug conjugates, with the deal being worth $1.2 billion depending on milestones.

1. Valeant Pharmaceutical release their latest price increases

Valeant Pharmaceutical have gained a certain notoriety of aggressive price hiking policy but announced on 14 October that their recent increases would range from 2.0% to 9.0%.

Related Content

Top 10 news roundup’s top 10 news stories of the week

Among our top 10 stories this week: A study has found the Pfizer COVID-19 vaccine …

Top 10 news roundup’s top 10 news stories of the week

A number of new COVID-19 developments have emerged in April already: AstraZeneca has halted the …

Top 10 news roundup’s top 10 news stories of the week

In the last week, a number of new COVID-19 developments have emerged; Novavax has delayed …

Latest content